Session Information

Sponsored Seminar

[ILS-FR-17] Lunch Seminar 17: Ranibizumab: transformational outcomes in patients with DME and RVO
Go back
print
Day
Apr 04 (Fri)
Time
12:15 - 13:15
Room
Room 2 - Tokyo International Forum 4,5F Hall C
Sponsor
Novartis Pharma AG
Topic
Retina, Vitreous body
Chair/Coordinator
Chair)Yuichiro Ogura、Chair)José Cunha-Vaz
Description
It is increasingly clear that, in DME and RVO, early-stage pathology is driven by VEGF. Consequently, physicians should endeavor to initiate early treatment using anti-VEGF agents. Comorbidities in patients with DME and RVO may mandate the use of anti-VEGF treatments with minimal systemic exposure to optimize the benefit-risk ratio. Data from recent clinical trials of ranibizumab demonstrate significant visual and anatomic improvements and minimal systemic exposure with an individualized treatment regimen. With the wealth of available evidence and its well-established safety profile, ranibizumab is a preferred option in the treatment of patients with DME and RVO (both BRVO and CRVO).

ILS-FR-17 / 

Retina, Vitreous body

Understanding the role and significance of VEGF inhibition in macular edema

Yuichiro Ogura José Cunha-Vaz

Understanding the role and significance of VEGF inhibition in macular edema

ILS-FR-17 / 

Retina, Vitreous body

From biology to practice: therapeutic interventions in macular edema

Ian Pearce

From biology to practice: therapeutic interventions in macular edema

ILS-FR-17 / 

Retina, Vitreous body

Evidence for individualized dosing: insights from recent anti-VEGF clinical trials

Christian Prünte

Evidence for individualized dosing: insights from recent anti-VEGF clinical trials

Go back